Kazia Therapeutics Limited (KZIA) 20-F2005 FY Annual report (foreign)

Filed: 23 Dec 05, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	8th grade Avg

New words: Abbey, Adjunct, ADM, AGAAP, alleged, arbitration, Archer, assimilate, AUD, Austin, avoided, barred, bdo, Belgium, binding, CAM, Cardiac, children, CHMP, classification, clerical, compliant, compromise, compulsory, conviction, Coronado, country, Denmark, diligence, Distinguished, El, Email, EMEA, error, EU, evasion, explanation, face, fail, false, focused, France, Geoffrey, Germany, glucoprime, GmbH, Greece, harmonize, healing, herbal, hire, HT, IFRIC, Immunologist, impractical, Indonesia, intersegment, intervening, intrasegment, intrinsic, isoflavoniod, Italy, Josiah, Kingdom, Koenig, KPMG, laundering, Luxembourg, Melbrosin, Midland, Monaco, multinational, notification, Oncology, organization, outsource, Ovature, parliament, partner, pediatric, pivotal, Portugal, predominately, prescribed, procure, progestin, ready, referral, refractory, reportedly, representation, resigned, Secretary, Society, Spain, split, subpopulation, Sweden, Switzerland, Tel, thereof, trialled, UIG, unavailable, undergone, unqualified, unusual, vasomotor, withdrawn, wrongdoing

Removed: acquitted, anti, assist, augment, automatically, began, bone, Cap, cholesterol, community, concept, conserve, construct, contravention, defending, deliberate, diminution, dishonesty, FAHA, faith, favor, financed, forecast, FRACP, FTSE, fundamental, hypothetical, impede, importance, improper, indemnify, inflammatory, intolerance, lose, MD, MEI, MEPL, neglect, occurrence, offence, oral, organisation, pound, predominantly, progression, ranging, restrained, revised, securing, showed, sick, spending, terminated, ultimate, undesirable, version, web, wider, world

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

KZIA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 13.1

Certification
Pursuant to Section 302
The Sarbanes-Oxley Act of 2002

Each of Christopher Naughton, Managing Director, and David Ross Seaton, Chief Financial Officer of Novogen Limited, a New South Wales corporation (the “Company”), hereby certifies that:

	(1)		The Company’s periodic report on form 20-F for the period ended June 30, 2005 (the “Form 20-F”) fully complies with the requirements of section 13(a) of the Securities Exchange Act of 1934 as amended; and

	(2)		The information contained in the Form 20-F fairly presents, in all material respects, the financial condition and results of operations of the Company.

***


Managing Director				Chief Financial Offer


Christopher Naughton				David Seaton

Date: December 23, 2005				Date: December 23, 2005